The most explicit call to date for expanding the use of active surveillance in the treatment of prostate cancer was made last week by the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of leading cancer centers. Updated guidelines from the group urge clinicians to offer active surveillance to their patients with prostate cancers that are at low risk of progressing to life-threatening disease. Read more > >
Guest Director's Update: Targeting Barriers, including Insurance Coverage, to Improve Clinical Trial Participation
by Andrea Denicoff and Dr. Jeffrey Abrams
Lack of health insurance coverage for the routine cost of care for patients taking part in clinical trials—including doctor visits, hospital stays, clinical laboratory tests, and other expenses—is a major barrier to participation. Read more > >
The president of the Oncology Nursing Society describes initiatives in oncology nursing that may be a model of the health care system Read more > >
A MESSAGE TO READERS
Follow Us on Twitter
The NCI Cancer Bulletin is now on Twitter. Follow @NCIBulletin for the latest cancer research news and information from our writers and editors. Please tell your colleagues and send us Tweets with your comments and questions.
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit .
NCI Cancer Bulletin staff can be reached at email@example.com.